Kevin Joseph Fitzgerald sold $1.1M of ALNY
CSO & EVP, Head of Research at ALNYLAM PHARMACEUTICALS, INC.. 2,441 shares at an average of $452.05, traded Oct 2, 2025, filed Oct 3, 2025.
Score components
- +15RoleOfficer
- +25Trade size$1.1M at market
- 0Share of holdings soldSold 8.8% of holdings
- +15Cluster5 insiders selling within 14 days
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001735276-25-000114, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Oct 1, 2025 | AGrant or award Common Stock | +2,102 | $0.00 | $0 | 24,821 | Oct 3, 2025 |
| Oct 1, 2025 | AGrant or award Common Stock | +2,851 | $0.00 | $0 | 27,672 | Oct 3, 2025 |
| Oct 2, 2025 | SOpen-market sale Common Stock | -96 | $446.53 | $43k | 27,576 | Oct 3, 2025 |
| Oct 2, 2025 | SOpen-market sale Common Stock | -47 | $447.92 | $21k | 27,529 | Oct 3, 2025 |
| Oct 2, 2025 | SOpen-market sale Common Stock | -150 | $448.77 | $67k | 27,379 | Oct 3, 2025 |
| Oct 2, 2025 | SOpen-market sale Common Stock | -207 | $449.79 | $93k | 27,172 | Oct 3, 2025 |
| Oct 2, 2025 | SOpen-market sale Common Stock | -449 | $450.81 | $202k | 26,723 | Oct 3, 2025 |
| Oct 2, 2025 | SOpen-market sale Common Stock | -276 | $451.86 | $125k | 26,447 | Oct 3, 2025 |
| Oct 2, 2025 | SOpen-market sale Common Stock | -555 | $452.69 | $251k | 25,892 | Oct 3, 2025 |
| Oct 2, 2025 | SOpen-market sale Common Stock | -273 | $453.77 | $124k | 25,619 | Oct 3, 2025 |
| Oct 2, 2025 | SOpen-market sale Common Stock | -203 | $454.84 | $92k | 25,416 | Oct 3, 2025 |
| Oct 2, 2025 | SOpen-market sale Common Stock | -60 | $455.82 | $27k | 25,356 | Oct 3, 2025 |
| Oct 2, 2025 | SOpen-market sale Common Stock | -122 | $457.43 | $56k | 25,234 | Oct 3, 2025 |
| Oct 2, 2025 | SOpen-market sale Common Stock | -3 | $457.64 | $1,373 | 25,231 | Oct 3, 2025 |
Related signals
Other insiders at ALNYLAM PHARMACEUTICALS, INC. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 36Weak | ALNYsell ALNYLAM PHARMACEUTICALS, INC. | Bryan Supran EVP, CLO and Secretary | $399k 1,758 shares | -12% | |
| 23Weak | ALNYLAM PHARMACEUTICALS, INC. | Kevin Joseph Fitzgerald CSO & EVP, Head of Research | $5.5M 12,128 shares | -36% | |
| 33Weak | ALNYLAM PHARMACEUTICALS, INC. | Yvonne Greenstreet Chief Executive Officer | $12M 25,650 shares | -32% | |
| 40Moderate | ALNYLAM PHARMACEUTICALS, INC. | Pushkal Garg EVP Chief R&D | $2.7M 5,959 shares | -23% | |
| 50Moderate | ALNYLAM PHARMACEUTICALS, INC. | Tolga Tanguler EVP, Chief Commercial Officer | $635k 1,405 shares | -5% | |
| 70Notable | ALNYLAM PHARMACEUTICALS, INC. | Yvonne Greenstreet Chief Executive Officer | $4.0M 8,924 shares | -12% | |
| 62Notable | ALNYLAM PHARMACEUTICALS, INC. | Jeffrey V. Poulton EVP, Chief Financial Officer | $1.7M 3,821 shares | -7% | |
| 33Weak | ALNYLAM PHARMACEUTICALS, INC. | Colleen F Reitan director | $8.4M 18,000 shares | -96% | |
| 40Moderate | ALNYLAM PHARMACEUTICALS, INC. | Tolga Tanguler EVP, Chief Commercial Officer | $1.6M 3,474 shares | -12% | |
| 30Weak | ALNYLAM PHARMACEUTICALS, INC. | Michael W Bonney director | $5.1M 11,250 shares | -40% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.